0001293310-19-000003.txt : 20191122 0001293310-19-000003.hdr.sgml : 20191122 20191122163503 ACCESSION NUMBER: 0001293310-19-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20191122 DATE AS OF CHANGE: 20191122 EFFECTIVENESS DATE: 20191122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HUMANIGEN, INC CENTRAL INDEX KEY: 0001293310 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770557236 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-354085 FILM NUMBER: 191242093 BUSINESS ADDRESS: STREET 1: 533 AIRPORT BLVD. STREET 2: SUITE 400 CITY: BURLINGAME STATE: CA ZIP: 94010 BUSINESS PHONE: 650.243.3100 MAIL ADDRESS: STREET 1: 533 AIRPORT BLVD. STREET 2: SUITE 400 CITY: BURLINGAME STATE: CA ZIP: 94010 FORMER COMPANY: FORMER CONFORMED NAME: KALOBIOS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20040609 D 1 primary_doc.xml X0708 D LIVE 0001293310 HUMANIGEN, INC 533 AIRPORT BLVD. SUITE 400 BURLINGAME CA CALIFORNIA 94010 650-243-3100 DELAWARE KALOBIOS PHARMACEUTICALS INC Corporation true Cameron Durrant 533 Airport Boulevard Suite 400 Burlingame CA CALIFORNIA 94010 Executive Officer Director Chief Executive Officer, Interim Chief Financial Officer, and Chairman of the Board Ronald Barliant 533 Airport Boulevard Suite 400 Burlingame CA CALIFORNIA 94010 Director Timothy Morris 533 Airport Boulevard Suite 400 Burlingame CA CALIFORNIA 94010 Director Robert Savage 533 Airport Boulevard Suite 400 Burlingame CA CALIFORNIA 94010 Director Rainer Boehm 533 Airport Boulevard Suite 400 Burlingame CA CALIFORNIA 94010 Director Pharmaceuticals Decline to Disclose 06b false 2019-11-08 true true false 0 20494614 494614 20000000 Amounts include common stock issued or issuable to Lincoln Park Capital Fund, LLC ("Lincoln Park") pursuant to the purchase agreement dated November 8, 2019 by and between Humanigen, Inc. and Lincoln Park. false 1 0 0 0 true Proceeds will be used to fund our obligations under collaboration and license agreements, pursue development and strategies for our product candidates,fund our obligations under secured bridge notes, and for general working capital and corporate purposes. false HUMANIGEN, INC CAMERON DURRANT CAMERON DURRANT CHAIRMAN AND CEO 2019-11-22